GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kineta Inc.
Kindly's value as a healthcare company is determined by its ability to commercialize its services. Its potential share price will depend on contracts with insurance companies and patient growth.
Share prices of companies in the market segment - Oncology immuno-therapy
Kineta, Inc. is a biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer. We've classified it in the "Immuno-Oncology" category, and the chart below shows how investors value companies at the forefront of immuno-oncology.
Broad Market Index - GURU.Markets
Kineta is an oncology company developing next-generation immunotherapy drugs. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Kineta shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
KA - Daily change in the company's share price Kineta Inc.
Kineta, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immuno-oncology drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Kineta is a biopharmaceutical company developing immunotherapy for cancer treatment. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and performance of KA stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Kineta is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kineta Inc.
For Kineta, Inc., year-over-year performance is a story about the development of its immuno-oncology drugs. Its 12-month market cap is entirely dependent on early clinical trial data. The success of its lead candidate, targeting VISTA, could offer a new approach to treating solid tumors, its primary scientific focus.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
As an early-stage biotech, Kineta is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kineta, a clinical-stage immuno-oncology company, is developing new cancer treatments. Its year-over-year market capitalization dynamics are a story of pure science and biotech risk. The chart reflects investor expectations for clinical data, not the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kineta Inc.
Kineta is a clinical-stage immuno-oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its leading programs is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
This chart reflects the dynamics of the volatile biotech sector. For Kineta, a clinical-stage company, it's the backdrop. Its movements show how the successes and failures of clinical trials in immuno-oncology have influenced investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kineta is a clinical-stage biotech developing immuno-oncology drugs. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Kineta's stock; its fate is decided in laboratories and clinics, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kineta Inc.
Kineta is a clinical-stage oncology company. Its weekly stock price, like that of other biotechs, is entirely dependent on news about the progress of clinical trials, which can cause sharp price fluctuations in either direction.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Kineta is a biotech company focused on immuno-oncology. It develops drugs that stimulate the immune response against cancer. The chart will help separate the company's performance from industry noise: are the weekly fluctuations driven by Kineta's progress or by general sentiment in this high-risk sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kineta is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
KA - Market capitalization of the company Kineta Inc.
The market capitalization chart of Kineta, a clinical-stage biotech, reflects investor confidence in its immuno-oncology drugs. Its valuation is speculative and depends entirely on the success of its clinical trials. Any data, positive or negative, causes sharp movements on the chart.
KA - Share of the company's market capitalization Kineta Inc. within the market segment - Oncology immuno-therapy
Kineta is a biotech company focused on immuno-oncology. Its market share in the pharmaceutical sector is virtually zero, which is typical for a company in early-stage research. Its market capitalization reflects solely investor confidence in its scientific platform and the potential of its future cancer treatments.
Market capitalization of the market segment - Oncology immuno-therapy
Here's a chart showing the biotech sector's market capitalization. Kineta is a company working in the field of immuno-oncology. Its research is focused on new targets that could help the immune system fight cancer. Its market history exemplifies how many small companies are pursuing scientific research that could lead to the next big breakthrough.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kineta is an oncology company developing immunotherapy drugs. Its market capitalization is based on the approval of its candidates. The chart below shows the economic weight of late-stage biotech companies developing cancer drugs.
Book value capitalization of the company, segment and market as a whole
KA - Book value capitalization of the company Kineta Inc.
Kineta's book value is derived from its equity and its scientific platform for developing immunotherapies for cancer treatment. The chart represents an early-stage biotech company investing all its resources in preclinical research to prove its ideas and attract further funding or partnerships.
KA - Share of the company's book capitalization Kineta Inc. within the market segment - Oncology immuno-therapy
Kineta is a biotech company focused on immuno-oncology. The chart shows its share of actual R&D assets. These are its laboratories where new drugs are being developed that can stimulate the immune system to fight cancer.
Market segment balance sheet capitalization - Oncology immuno-therapy
Kineta is a biotech company working in the field of immuno-oncology. Their main assets are patents and clinical trial results, not manufacturing facilities. A book value chart will show the value of their laboratories, but it won't reflect the potential of their research.
Book value of all companies included in the broad market index - GURU.Markets
Kineta's balance sheet includes laboratories and R&D centers for developing new immuno-oncology drugs. The chart shows how the company is building its scientific and material foundation for creating innovative cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kineta Inc.
Kineta is a biotech company working in the field of immuno-oncology. Its assets are intangible and consist of scientific research. The chart below is a visualization of its venture capital investment. The market capitalization is a bet on the success of its cancer treatment approaches and is not related to its current balance sheet.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Kineta is a clinical-stage biotech developing cancer immunotherapy drugs that target innate immunity. Its valuation is entirely dependent on clinical trial results. This schedule reflects the high risk and potential of its innovative scientific approach.
Market to book capitalization ratio for the market as a whole
Kineta is a biotech company focused on immuno-oncology. Its market value is almost entirely dependent on the success of its clinical programs. This chart demonstrates the typical biotech gap between the market valuation based on the future potential of its drugs and the current book value of its assets.
Debts of the company, segment and market as a whole
KA - Company debts Kineta Inc.
Kineta, Inc. is a clinical-stage biotechnology company focused on immuno-oncology. This chart shows its financial position. With no revenue, the company relies entirely on equity capital to fund its research and development of new cancer treatments.
Market segment debts - Oncology immuno-therapy
Kineta is a clinical-stage biotech focused on immuno-oncology. Its survival depends on research results and its ability to attract funding. This chart clearly illustrates the high financial risk and significant capital requirements inherent in this industry.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kineta Inc.
Kineta is a clinical-stage immuno-oncology company. This chart shows its financial structure. As with most biotechs without stable revenue, debt is a huge risk. All resources should be focused on research, not interest payments.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Kineta is a clinical-stage biopharmaceutical company developing immuno-oncology drugs. This chart shows the debt burden in the biotech sector. It is a key indicator of a company's ability to fund its expensive research and development in this highly competitive field.
Debt to book value of all companies in the market
Kineta is a clinical-stage biopharmaceutical company focused on immuno-oncology. Its future depends on the success of clinical trials and access to financing. This chart of total market debt serves as a barometer of the investment climate, showing how easy or difficult it is for companies like Kineta to raise funds for their developments.
P/E of the company, segment and market as a whole
P/E - Kineta Inc.
Kineta is a biotech company developing immunotherapeutic drugs for cancer treatment. This chart reflects the high risks associated with early-stage clinical development. Its dynamics depend entirely on news of trial results.
P/E of the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biotech company developing a new generation of immuno-oncology therapies. Its goal is to create drugs that will be effective in patients with "cold" tumors that are unresponsive to existing immunotherapies. This chart shows the average valuation for the immuno-oncology sector, reflecting how investors evaluate cutting-edge scientific approaches.
P/E of the market as a whole
Kineta is a biotech company developing immuno-oncology drugs. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Kineta's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kineta Inc.
Kineta is a biotech company developing immunotherapeutic drugs for the treatment of cancer. This chart reflects investors' confidence in the potential of its scientific developments. Future profits are entirely dependent on the success of clinical trials and the ability to offer effective treatments for cancer patients.
%20P%2FE%20Kineta%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kineta-Inc.&v=1772574853603 "Chart of the company's future (projected) P/E Kineta Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biopharmaceutical company developing immunotherapy for solid tumors. The chart reflects average expectations for the oncology segment. KA's position relative to this benchmark reflects investor assessment of its scientific approach, which aims to activate the immune system to fight cancers resistant to existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772574853634 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Kineta is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics for the treatment of cancer. The company targets novel mechanisms for activating the immune system against tumors. This chart of overall market expectations illustrates investor appetite for risk associated with early-stage oncology funding.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772574853708 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kineta Inc.
Kineta, Inc. is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer. Its financial schedule is based on clinical trial expenses. Potential profitability depends on whether its drug candidates prove effective in the fight against cancer.
Profit of companies in the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biopharmaceutical company developing innovative immunotherapeutics for the treatment of solid tumors. Its approach is aimed at stimulating innate immunity. This chart shows the overall profitability of the immuno-oncology sector, reflecting the willingness of investors to fund cutting-edge scientific concepts in the fight against cancer.
Overall market profit
Kineta, Inc. is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer. Its focus is on innate immunity. The company's success depends on the results of clinical trials. The positive economic environment, visible in this chart, is critical to attracting the investment needed to advance its innovative programs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kineta Inc.
Kineta is a clinical-stage biopharmaceutical company developing immunotherapeutic drugs for the treatment of cancer. This chart reflects analysts' speculative expectations regarding the potential of its research projects, which are aimed at stimulating the immune response against tumors.
%20profit%20of%20the%20company%20Kineta%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kineta-Inc.&v=1772574853965 "Graph of future (projected) profit of the company Kineta Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Kineta is a biotech company developing immunotherapeutic drugs for the treatment of oncology. Its approach is aimed at activating the immune system to fight cancer. The company's future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing the potential and risks of Kineta's innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772574854011 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Kineta, Inc. is a biotechnology company developing immunotherapeutic drugs for the treatment of cancer. Its prospects are entirely dependent on success in clinical development. The overall economic indicators presented in this chart are not directly related to its current operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772574854029 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kineta Inc.
Kineta is a clinical-stage biotech focused on immuno-oncology. Its valuation, shown on this chart, is based not on current revenue but on the potential of its scientific developments. The dynamics are a direct reaction from investors to news about the progress of clinical trials and the efficacy of its drugs.
P/S market segment - Oncology immuno-therapy
Kineta is a biopharmaceutical company developing immunotherapies for the treatment of cancer. Future revenue depends on the success of its clinical programs. This oncology chart reflects investor expectations for the potential of Kineta's innovative drugs to stimulate the immune system in the fight against tumors.
P/S of the market as a whole
Kineta is a clinical-stage biotech company developing novel immunotherapeutic drugs for cancer. This market revenue valuation chart helps understand how investors assess the scientific potential and risks associated with drug development in one of the most competitive areas of pharmaceuticals.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kineta Inc.
Kineta is a clinical-stage biotechnology company focused on developing innovative immunotherapeutic agents for the treatment of solid tumors. This chart shows how the market assesses the future commercial potential of its developments. It reflects investor expectations for the success of clinical trials.
%20P%2FS%20Kineta%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kineta-Inc.&v=1772574854121 "The graph of the company's future (projected) P/S Kineta Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biotechnology company developing novel immunotherapeutic drugs for the treatment of cancer. The company's valuation is based on investors' confidence in its scientific approach and the potential of its candidates to stimulate the immune system to fight tumors, a high-risk but promising area.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772574854154 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Kineta, Inc. is a biotechnology company developing a new generation of immuno-oncology drugs. Its goal is to "awaken" the immune system to fight cancer. In the context of the overall revenue projections shown in the chart, Kineta represents a venture capital investment in the future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772574854175 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kineta Inc.
Kineta is a clinical-stage immuno-oncology company developing novel cancer treatments. The company currently has no commercial products and, therefore, no sales revenue. Any revenue reflected in the chart likely comes from grants or partnerships.
Sales of companies in the market segment - Oncology immuno-therapy
Kineta (KA) is a biotech company developing immunotherapeutic drugs for the treatment of cancer. Its goal is to create therapies that can effectively combat "cold" tumors that are unresponsive to existing treatments. This metric reflects revenue in the immuno-oncology sector. Kineta is working to solve one of the most complex problems in modern oncology.
Overall market sales
Kineta is a biotech company developing immunotherapeutic drugs for cancer treatment. Its future depends on success in clinical trials. This pattern of overall economic activity influences the investment climate in the biotech sector. During periods of growth, investors are more inclined to fund companies with innovative but risky approaches to immuno-oncology.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kineta Inc.
Kineta is a biotech company developing immunotherapeutic drugs for the treatment of cancer. Its future revenue is entirely dependent on the success of its candidates in clinical trials. This chart reflects analyst forecasts, which are essentially an assessment of the scientific potential and commercial prospects of its immuno-oncology developments.
%20sales%20of%20the%20company%20Kineta%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kineta-Inc.&v=1772574854294 "Schedule of future (projected) sales of the company Kineta Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. This forecast chart reflects the potential future revenue from their pipeline of candidates. It represents analysts' perspective on the commercial prospects of their innovative approaches in oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772574854324 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Kineta is a biotech company developing new immunotherapies for cancer treatment. Its goal is to stimulate the immune system to fight tumors that are unresponsive to existing treatments. This graph reflects the overall investment climate, and Kineta's research progress is a bet on a scientific breakthrough in one of the most challenging areas of oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772574854371 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kineta Inc.
Kineta, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of solid tumors. Its financial metrics reflect R&D expenses. The chart shows the company's current financial performance, whose future profitability is entirely dependent on the success of its innovative approaches to cancer treatment.
Market segment marginality - Oncology immuno-therapy
Kineta is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic agents for the treatment of cancer. This chart reflects its operating expenses. Future profitability is entirely dependent on the success of its clinical programs and the ability to demonstrate the efficacy of its innovative approaches.
Market marginality as a whole
Kineta, Inc. is a clinical-stage biotech developing immunotherapy for cancer. Its future depends on successful trials and raising capital. This total return chart reflects the investment climate. A favorable economic environment, with companies generally profitable, facilitates raising capital for risky biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Kineta Inc.
Kineta is a biopharmaceutical company focused on immuno-oncology. It develops drugs that stimulate the innate immune system to fight cancer cells. This graph shows its scientific team working on a new treatment approach, aiming to make immunotherapy more effective.
Share of the company's employees Kineta Inc. within the market segment - Oncology immuno-therapy
Kineta is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. Its staff consists of a small but highly qualified team of scientists and clinicians. This chart shows the amount of intellectual capital the company invests in research to advance its innovative approaches in oncology.
Number of employees in the market segment - Oncology immuno-therapy
Kineta, Inc. is a biopharmaceutical company developing immunotherapies for cancer treatment. This graph, showing employment in immuno-oncology, illustrates how competitive and rapidly evolving this field is. For Kineta, with their focus on innate immunity, growth in this field means both scientific advancement and the need to prove the uniqueness of their approach.
Number of employees in the market as a whole
Kineta is a biotech company developing innovative immunotherapeutic drugs. Like many companies in this field, its growth depends on raising capital. A strong economy, reflected by the growth in overall employment in this chart, creates a favorable financial market environment for supporting long-term, high-risk R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kineta Inc. (KA)
Kineta (KA) is a biotech company working in the field of immuno-oncology. As with any biotech company in the R&D stage, this chart shows the market valuation of their scientific platform. Their market capitalization is not dependent on their headcount, but is determined solely by the potential of their developments and the value of their intellectual property.
%20of%20the%20company%20Kineta%20Inc.%20(KA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kineta-Inc.-KA&v=1772574854654 "Chart of market capitalization per employee (in thousands of dollars) of the company Kineta Inc. (KA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Kineta is a biopharmaceutical company focused on immuno-oncology. Its value is determined by its pipeline of potential drugs. This chart demonstrates the high future value the market attributes to its research, based on its relatively small team of scientists.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772574854672 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Kineta is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its value depends on the success of its research. This chart for Kineta is a prime example of a biotech company where the market value per employee can be colossal, reflecting investors' hopes for breakthrough drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772574854687 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kineta Inc. (KA)
Kineta is a biotech R&D company working in the field of immuno-oncology. The company is unprofitable. This graph will show a negative value—the loss per scientist. This reflects the high cost of cutting-edge research in this field.
%20Chart%20Kineta%20Inc.%20(KA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kineta-Inc.-KA&v=1772574854713 "Company Profit Per Employee (in thousands of dollars) Chart Kineta Inc. (KA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Kineta, Inc. is a biotechnology company developing immunotherapies for the treatment of cancer. In this cutting-edge field, the productivity of each scientist is critical to success. This chart shows the potential value each employee creates, which is an indicator of the effectiveness of R&D investments.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772574854728 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Kineta is a biotech company developing immuno-oncology drugs designed to "wake up" the immune system to fight cancer. This is pure R&D. This graph shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be colossal if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772574854756 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kineta Inc. (KA)
Kineta is a clinical-stage biotech company developing immunotherapeutic drugs for cancer treatment. Since it has no commercial products yet, it has no revenue per employee. This chart clearly illustrates the R&D phase, where the team is focused entirely on conducting clinical trials for its innovative treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kineta-Inc.-KA&v=1772574854776 "Sales chart per company employee Kineta Inc. (KA)")
Sales per employee in the market segment - Oncology immuno-therapy
Kineta (KA) is a clinical-stage biotech company specializing in the development of immunotherapies for cancer treatment. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and staff structure compared to other early-stage oncology biotechs.
Sales per employee for the market as a whole
Kineta (KA) is a clinical-stage biotech company focused on developing novel immunotherapies for cancer treatment. The company has no commercial revenue. This near-zero metric reflects ongoing investment in its R&D team, working to create new drugs in this competitive field.
Short shares by company, segment and market as a whole
Shares shorted by company Kineta Inc. (KA)
Kineta (KA) is a clinical-stage microcap biotech focused on immuno-oncology. This chart shows short interest. The high bearish bets reflect the enormous risks of clinical trials, high cash burn, and concerns that the company will run out of cash before it can prove the effectiveness of its drugs. (342)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kineta-Inc.-KA&v=1772574855022 "Short Shares Chart for the Company Kineta Inc. (KA)")
Shares shorted by market segment - Oncology immuno-therapy
Kineta (KA) is a biopharmaceutical company developing new immunotherapies for the treatment of cancer. The chart below shows a general short position in the oncology biotech sector. It demonstrates the general investor skepticism regarding the success of risky clinical trials in this field.
Shares shorted by the overall market
Kineta (KA) is a clinical-stage biotech company working in immuno-oncology. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures like KA, fearing they'll run out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kineta Inc. (KA)
This oscillator for Kineta is a clear barometer of hope in immuno-oncology. The company is developing drugs to "awaken" the immune system against cancer. This is the binary events sector. Any positive data hinting at efficacy triggers "overheating" (above 70). A trial failure, delay, or the need to raise capital immediately collapses the indicator (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kineta-Inc.-KA&v=1772574855167 "RSI 14 indicator chart for the company's stock Kineta Inc. (KA)")
RSI 14 Market Segment - Oncology immuno-therapy
Kineta (KA) is a biotech focused on immuno-oncology, the search for new ways to "activate" immunity against cancer. KA shares could soar on data, but they could also sink in the general industry pessimism. This chart shows the collective sentiment of the entire biotech sector. It helps us understand whether Kineta is capitalizing on its unique science or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
For Kineta, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KA (Kineta Inc.)
Kineta is a biotech focused on developing next-generation immuno-oncology therapies targeting innate immunity (VISTA, RIG-I). This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of the company's R&D portfolio and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KA-Kineta-Inc.&v=1772574855348 "A chart showing analyst consensus forecasts for the expected stock price. KA (Kineta Inc.)")
The difference between the consensus estimate and the actual stock price KA (Kineta Inc.)
Kineta (KA) is a biotech company developing a new generation of immunotherapy (VISTA) for the treatment of "cold" tumors that are unresponsive to existing treatments. This chart shows how the current share price differs from its "fair" value. It reflects the "venture capital" valuation of their R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KA-Kineta-Inc.&v=1772574855399 "A chart showing the difference between the consensus forecast and the actual stock price. KA (Kineta Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Kineta (KA) is a clinical-stage biotech focused on developing novel cancer immunotherapies. Like all R&D firms, its value is driven by data and sentiment. This chart reflects the collective opinion of the *entire* immuno-oncology sector. It shows whether experts continue to fund moonshot R&D projects.
Analysts' consensus forecast for the overall market share price
Kineta is a biotech company specializing in cancer immunotherapy development. This is a high-risk sector. This chart reflects the overall market "risk appetite." For Kineta, a clinical-stage company, overall market optimism (the rising chart) is critical for raising the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kineta Inc.
Kineta is a biotech R&D company focused on immuno-oncology. Their specialty is the R&D of drugs (antibodies) targeting new checkpoints (VISTA), which (in theory) should stimulate immunity against cancer. This chart is a pure R&D barometer of faith/fear. It reflects not sales, but the market's speculative valuation of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - Oncology immuno-therapy
Kineta (KA) is an immuno-oncology company. They develop drugs that re-educate the immune environment inside tumors, making cold tumors hot and vulnerable to attack. This chart compares their composite index to the sector, showing how their R&D approach compares to others.
The AKIM Index for the overall market
Kineta is a biotech company developing an immunotherapy for cancer treatment (anti-VISTA). It is undergoing a strategic review. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company fares in this challenging environment against the backdrop of overall economic trends.
